A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas.
The objective was to discover whether the oxygen-regulated protein, metallothionein, is expressed in the hypoxic cells of squamous cell carcinomas. Twenty patients with squamous cell carcinoma of the uterine cervix or head and neck were infused with a solution of the hypoxia marker, pimonidazole hydrochloride, at a dose of 0.5 g/m2. The following day, biopsies were collected, formalin fixed, paraffin embedded, and sectioned at 4 microm. Sections from each biopsy were immunostained for pimonidazole binding, metallothioneins I and II, involucrin, and proliferating cell nuclear antigen. A total of 84 biopsies were analyzed. Sixty-four of 84 biopsy sections contained hypoxia. Of the hypoxia-containing sections, 43 of 64 or 67% showed no microregional overlap between hypoxia and metallothionein; 7 of 64 showed overlap; and 14 of 64 showed a combination of overlap and no overlap. On a tumor-by-tumor basis, 5 of 7 head and neck and 7 of 13 cervix tumors showed no overlap between metallothionein and hypoxia at the microregional level. Ranges for the percentage of the area of hypoxia in head and neck (<0.9 to 17%) and cervix (<0.1 to 14%) tumors were similar. In the hypoxia-containing sections, immunostaining for involucrin, a molecular marker for differentiation, overlapped with that for hypoxia in 82% of the cases. The majority of hypoxic cells in squamous cell carcinomas do not express metallothionein protein, although metallothionein is induced by hypoxia in human tumor cells in vitro. Hypoxic cells in human tumors tend to be in regions immunostaining for involucrin, and it seems possible that differentiation of hypoxic cells in squamous cell carcinomas might affect metallothionein I and II expression.
Raleigh
J A
JA
Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill 27599, USA. raleigh@radonc.unc.edu
Chou
S C
SC
Calkins-Adams
D P
DP
Ballenger
C A
CA
Novotny
D B
DB
Varia
M A
MA
D015415:Biomarkers / Q000032:analysis; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000473:pathology; D015687:Cell Hypoxia; D005260:Female; D006258:Head and Neck Neoplasms / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D008668:Metallothionein / Q000032:analysis / Q000096:biosynthesis*; D009367:Neoplasm Staging; D009593:Nitroimidazoles / Q000008:administration & dosage / Q000378:metabolism; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis; D011498:Protein Precursors / Q000032:analysis; D002583:Uterine Cervical Neoplasms / Q000378:metabolism* / Q000473:pathology
D015415:Biomarkers; D009593:Nitroimidazoles; D018809:Proliferating Cell Nuclear Antigen; D011498:Protein Precursors; C033815:pimonidazole; C032253:involucrin; D008668:Metallothionein